Black Diamond Therapeutics (BDTX) Cash from Financing Activities (2019 - 2026)
Black Diamond Therapeutics (BDTX) posted Cash from Financing Activities of -$185000.0 for Q1 2026, up 5.61% on a QoQ basis from -$196000.0 in Q4 2025, and down 678.12% year-over-year from $32000.0 in Q1 2025.
Black Diamond Therapeutics (BDTX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$185000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 678.12% year-over-year to -$185000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$363000.0 (down 101.69% YoY) and the FY2025 annual result came in at -$146000.0, down 100.57% from the prior year.
- Cash from Financing Activities was -$185000.0 for Q1 2026 at Black Diamond Therapeutics, up from -$196000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $71.9 million in Q3 2023 and bottomed at -$252000.0 in Q3 2024.
- A 5-year average of $6.5 million and a median of $51000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 138221.15% — and 2026, when it tumbled 678.12%.
- Black Diamond Therapeutics' Cash from Financing Activities stood at -$28000.0 in 2022, then tumbled by 64.29% to -$46000.0 in 2023, then soared by 732.61% to $291000.0 in 2024, then plunged by 167.35% to -$196000.0 in 2025, then gained by 5.61% to -$185000.0 in 2026.
- Business Quant data shows BDTX's Cash from Financing Activities at -$185000.0 in Q1 2026, -$196000.0 in Q4 2025, and $134000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 238.74 Mn |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - | -185,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -185,000.00 |
| Mar 31, 2026 | -185,000.00 |
| Dec 31, 2025 | -196,000.00 |
| Dec 31, 2025 | -196,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Jun 30, 2025 | -116,000.00 |
| Jun 30, 2025 | -116,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | 291,000.00 |
| Dec 31, 2024 | 291,000.00 |
| Sep 30, 2024 | -252,000.00 |
| Sep 30, 2024 | -252,000.00 |
| Jun 30, 2024 | 21.38 Mn |
| Jun 30, 2024 | 21.38 Mn |
| Mar 31, 2024 | 4.13 Mn |
| Mar 31, 2024 | 4.13 Mn |
| Dec 31, 2023 | -46,000.00 |
| Dec 31, 2023 | -46,000.00 |